OncoMatch/Clinical Trials/NCT07362979
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Is NCT07362979 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including GP plus Toripalimab Induction chemotherapy+CCRT and TP plus Toripalimab Induction chemotherapy+CCRT for nasopharyngeal cancinoma (npc).
Treatment: GP plus Toripalimab Induction chemotherapy+CCRT · TP plus Toripalimab Induction chemotherapy+CCRT · TPC plus Toripalimab Induction chemotherapy+CCRT — This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the treatment of locally advanced nasopharyngeal carcinoma (NPC). The study is aimed to pick up the most effective platinum-based induction chemotherapy regimen plus Toripalimab for these patients which provides the most survival benefit.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage ANY T, N2-3, T4, N1 (AJCC 9th edition)
Excluded: Stage DISTANT METASTASIS (M1)
Stage Any T, N2-3 or T4, N1 (AJCC 9th edition staging), with no distant metastasis (M0). Patients with nasopharyngeal carcinoma presenting with recurrence or distant metastasis [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Prior history of radiotherapy
Cannot have received: systemic chemotherapy
Prior history of systemic chemotherapy
Cannot have received: immune checkpoint inhibitor (CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor)
Patients previously treated with immune checkpoint inhibitors (e.g., CTLA-4, PD-1, PD-L1 inhibitors)
Cannot have received: anticancer monoclonal antibody
Exception: within 4 weeks prior
Patients who have received high-dose glucocorticoids, anticancer monoclonal antibodies, or other immunosuppressive therapy within 4 weeks prior
Cannot have received: immunosuppressive therapy
Exception: within 4 weeks prior
Patients who have received high-dose glucocorticoids, anticancer monoclonal antibodies, or other immunosuppressive therapy within 4 weeks prior
Lab requirements
Blood counts
Hemoglobin (HGB) ≥ 90g/L, Absolute Neutrophil Count (ANC) ≥ 1.5×10^9/L, and Platelet (PLT) ≥ 100×10^9/L
Kidney function
Serum creatinine ≤ 1.5×ULN or calculated creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault formula)
Liver function
ALT and AST ≤ 2.5×ULN, total bilirubin ≤ 2.0×ULN, and serum albumin ≥ 30g/L
Adequate hematological function: Hemoglobin (HGB)≥90g/L, Absolute Neutrophil Count (ANC) ≥ 1.5*10^9/L, and Platele (PLT) ≥100*10^9/L. Adequate hepatic function: ALT and AST≤2.5*Upper Limit of Normal (ULN), total bilirubin ≤2.0*ULN, and serum albumin≥30g/L. Adequate renal function: Serum creatinine ≤ 1.5*ULN or calculated creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07362979 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage ANY T, N2-3 or T4, N1 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages